AOD-9604 in Flavignac — Fat Loss Peptide Research Guide
AOD-9604 research guide for Flavignac. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Flavignac trying to locate AOD-9604, the key fact to understand is that this compound is available only through an online research supply market. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than local retail ever could. Separating genuine research-grade AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Flavignac researchers need to know about sourcing, verifying, and handling AOD-9604 for research purposes.
The Science Behind AOD-9604
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Flavignac researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade AOD-9604
The first step for any Flavignac researcher sourcing AOD-9604 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with negligible secondary peaks representing impurities — purity should be stated as ≥98%. For Flavignac researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is standard practice in the community. The lyophilised (freeze-dried) form of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Flavignac
COA-verified · International tracking · Research grade
AOD-9604 operates outside the framework of pharmaceutical oversight — researchers should understand that the known safety profile is based on academic studies rather than pharmaceutical approval data. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Quality AOD-9604 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. Researchers running multi-compound protocols with AOD-9604 should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
